View Future GrowthZhongchao 과거 순이익 실적과거 기준 점검 0/6Zhongchao 의 수입은 연평균 -42.1%의 비율로 감소해 온 반면, Consumer Services 산업은 연평균 25.6%의 비율로 증가했습니다. 매출은 연평균 4.6%의 비율로 감소해 왔습니다.핵심 정보-42.15%순이익 성장률-33.41%주당순이익(EPS) 성장률Consumer Services 산업 성장률20.27%매출 성장률-4.56%자기자본이익률-25.73%순이익률-55.47%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Apr 06Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024)Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024).Reported Earnings • Oct 05First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024)First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 27Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023)Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 02Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022)Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.Reported Earnings • Dec 27First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.Reported Earnings • May 14Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021)Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesReported Earnings • Apr 06Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024)Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024).New Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 126% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (126% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).분석 기사 • Feb 13Zhongchao Inc. (NASDAQ:ZCMD) Looks Inexpensive After Falling 60% But Perhaps Not Attractive EnoughZhongchao Inc. ( NASDAQ:ZCMD ) shareholders that were waiting for something to happen have been dealt a blow with a 60...New Risk • Feb 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$7.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).New Risk • Dec 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$18.9m market cap).분석 기사 • Dec 30Some Zhongchao Inc. (NASDAQ:ZCMD) Shareholders Look For Exit As Shares Take 32% PoundingTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 32% in the last...Reported Earnings • Oct 05First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024)First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.분석 기사 • Sep 20Zhongchao Inc. (NASDAQ:ZCMD) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedZhongchao Inc. ( NASDAQ:ZCMD ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$24.0m market cap).분석 기사 • Jun 22What Zhongchao Inc.'s (NASDAQ:ZCMD) 28% Share Price Gain Is Not Telling YouZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...분석 기사 • Jun 19Here's Why We're Watching Zhongchao's (NASDAQ:ZCMD) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$33.6m market cap).Reported Earnings • Apr 27Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023)Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.분석 기사 • Feb 28Zhongchao Inc.'s (NASDAQ:ZCMD) Popularity With Investors Is Under Threat From OverpricingIt's not a stretch to say that Zhongchao Inc.'s ( NASDAQ:ZCMD ) price-to-sales (or "P/S") ratio of 1.8x right now seems...분석 기사 • Nov 15Zhongchao Inc.'s (NASDAQ:ZCMD) 32% Dip In Price Shows Sentiment Is Matching RevenuesZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a horrible month, losing 32% after a relatively good period beforehand...공시 • Nov 07Zhongchao Inc., Annual General Meeting, Dec 18, 2024Zhongchao Inc., Annual General Meeting, Dec 18, 2024, at 09:00 China Standard Time. Location: nanxi creative center, suite 218, 841 yanan middle road, jingan district, shanghai, ChinaNew Risk • Oct 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 116% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).공시 • Oct 02Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million.Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 3,094,000 Price\Range: $0.3 Discount Per Security: $0 Transaction Features: Registered Direct Offering분석 기사 • Oct 01Zhongchao Inc. (NASDAQ:ZCMD) Surges 76% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Zhongchao Inc. ( NASDAQ:ZCMD ) shares have been powering on, with a gain of 76% in the...New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Market cap is less than US$10m (US$3.39m market cap).분석 기사 • Aug 10Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryZhongchao Inc. ( NASDAQ:ZCMD ) shareholders would be excited to see that the share price has had a great month, posting...Reported Earnings • May 02Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022)Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.분석 기사 • Apr 27Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryThose holding Zhongchao Inc. ( NASDAQ:ZCMD ) shares would be relieved that the share price has rebounded 32% in the...분석 기사 • Mar 07Benign Growth For Zhongchao Inc. (NASDAQ:ZCMD) Underpins Stock's 30% PlummetTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 30% in the last...분석 기사 • Dec 28Little Excitement Around Zhongchao Inc.'s (NASDAQ:ZCMD) Revenues As Shares Take 50% PoundingUnfortunately for some shareholders, the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has dived 50% in the last thirty...Reported Earnings • Dec 27First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$20.8m market cap).New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$22.4m market cap).공시 • Sep 26Zhongchao Inc. Introduces Pro-Based Disease Management Model for Lung Cancer PatientsZhongchao Inc. announced the introduction of its Patient-Reported Outcome (PRO)-based symptom management model. This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality. Many lung cancer patients are grappling with a multitude of symptoms throughout their treatment process, including but not limited to fatigue, reduced appetite, nausea, and approximately 34 other symptoms. These symptoms can lead to emotional turmoil towards patients, manifesting as anxiety or depression, severely impacting patients' life quality and their overall recovery process. The PRO-based symptom management method prioritizes genuine feedbacks from patients about their health conditions, which aids in accurately identifying underlying health concerns and enhancing overall well-being. A study published in the "Journal of Clinical Oncology" in 2022 also highlighted that a PRO-driven model integrating proactive Symptom Monitoring, Alerting, and Response System can significantly reduce post-discharge symptoms and complications in lung cancer patients, accelerate their post-operative recovery and receive high satisfaction from patients. Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients. The expert-led seminars could guide patients and offer direct engagement through mobile applications to answer their queries virtually. The seminars ensure patients fully understand their treatment journey and can enhance their adherence to treatment protocols. Zhongchao also provides a suite of resources through mobile applications, including, among the others, educational contents, disease follow-up visits, lifestyle advice, drug aids information and other support services. To facilitate efficient and one-on-one patient communications, Zhongchao has established robust follow-up channels through various platforms such as phones, WeChat, and text messages, staffed by dedicated disease management specialists. Unlike the existing patient management services, which focus primarily on medical aspects such as Duration of Therapy, the newly introduced PRO-based management model shifts the focus towards patients' own experiences and feelings about their health, bringing a fresh perspective into patient care. By actively collecting and analyzing patient feedback on physical symptoms, emotional states, self-perceptions and other PRO data, the Company is able to continually refine its management methods, aiming to enhance the living standards and well-being of lung cancer patients.Reported Earnings • May 14Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021)Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.공시 • Feb 09Zhongchao Inc. Announces the Application of ChatGPT to Elevate Patient Management Service Capabilities and ExperienceZhongchao Inc. announced the application of ChatGPT (Chat Generative Pre-trained Transformer) for content creation and patient interactions to enhance the capabilities in delivering quality experience of patient management services. ChatGPT is a language model developed by OpenAI that learns and produces conversational content through natural language processing powered by artificial intelligence technology to interact with users in chat and continuously learn to improve the user experience. The Sunshine Health Forums and Zhongxin, both operated by the PRC operating entities that Zhongchao consolidates the financial statements with through certain contractual agreements, provide medical knowledge education and treatment process management services with patients through a comprehensive array of resources, including media matrix, anti-cancer encyclopedia, online consultation, and medication management. These platforms offer patients with instant answers and clarifications for complex and professional issues and questions encountered during self-diagnosis, diagnostic and treatment process, serving as a valuable reference for patients' consultation, treatment, and health maintenance. Given the wide variety of human diseases and the huge amount of medical information, patient management requires efficient production of massive medical content and prompt patient interactions. In a further effort to enhance patient experience, Zhongchao will apply ChatGPT on the existing platforms of Wechat Public Account and Mini-Program on WeChat to improve the efficiency of producing graphics, videos, and other contents, promptly respond and interact with patients, and manage patient emotions and experiences. Zhongchao places a strong emphasis on delivering a superior patient experience. In addition, patients will be alerted that contents provided by ChatGPT will be solely for reference and convenience to users and shall not be relied on for diagnostic or treatment purposes. To address patients' demand for personalized services, the Company may plan to harness ChatGPT's power of advanced thinking and computing capabilities to develop customized disease management models and intelligent tools that cater to the specific needs and conditions of each patient, ensuring patients receiving individualized and tailored services regardless of their varying disease types, stages, health conditions, and mental states.Reported Earnings • Dec 18First half 2022 earnings released: EPS: US$0.004 (vs US$0.04 in 1H 2021)First half 2022 results: EPS: US$0.004 (down from US$0.04 in 1H 2021). Revenue: US$7.30m (down 15% from 1H 2021). Net income: US$93.5k (down 91% from 1H 2021). Profit margin: 1.3% (down from 12% in 1H 2021). The decrease in margin was driven by lower revenue.공시 • Dec 06Zhongchao Inc. Establishes SID Liver Cancer Comprehensive-Disciplinary Physician Education PlatformZhongchao Inc. announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer. The SID Platform created by Zhongchao targets physicians from different levels and covers comprehensive disciplines of liver cancer treatment: hepatobiliary surgery, interventional and medical oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer disciplines, the SID Platform designs and provides clinical diagnosis and treatment education courses in liver cancer and provides a technical platform for clinicians to share experiences and discuss clinical challenges. As of now, the courses on the SID Platform were taken approximately 290,000 times by liver cancer physicians. Zhongchao believes that its SID Platform provides a platform for liver cancer physicians, especially for junior and intermediate physicians to present themselves, learn knowledge and techniques, and communicate with peers, which promotes new liver cancer treatment concepts such as conversion therapy, comprehensive patient management and standardized interventional treatments. Zhongchao expects its SID Platform to serve as a new model of promotion and education platform, contribute to the lifelong learning and professional development of liver cancer physicians, and eventually benefit liver cancer patients.Board Change • Dec 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Kevin Dean Vassily was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Sep 02Zhongchao Inc. Announces Its New Strategy Extension Focusing on the Oncology and Other Major Disease ManagementZhongchao Inc. announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services. The Company has implemented several strategic initiatives to transform to the new "Medical-Pharmaceutical-Patient" model. In 2021, Zhongchao launched patient management business focusing on the professional field of tumor and rare disease through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin"), which was the important first step of the transform. The strategy to extend business model was driven by the increased demands of "patient-oriented" healthcare in China. Management have been closely observing and monitoring such service model that is to provide medical services and disease management tailored to individual patient and allow patient to actively initiate and participate in health management and disease treatment since its appearance in 2021. It is worth to mention that the Company's self-developed patient management system successfully improved Duration of Therapy ("DOT") by 40.4% for liver cancer patients, contributing to the maximum efficiency of drugs, successful treatment and longer patient survival terms, as compared to patients without using the management system, based on the data collected by the Company during a period from November 2017 to September 2021. As a result, the Company plans to continue the development of patient management services through Zhongxin. As of now, Zhongxin provides comprehensive disease education and management services for tumor patients receiving treatment. Through services such as drug aids, disease follow-up visits, medication management, and cancer education promotion, Zhongxin helps tumor patients reduce the economic burden of treatment and promote the completion the treatment process, resulting in the best treatment effect and improvement the quality of life for the patients. As of now, more than hundreds of thousand oncology Patients have used either the application developed by Zhongxin or WeChat network service platform to connect patients with Zhongxin's hotline center and service commissioner system and received disease management support.공시 • Jun 15Zhongchao Inc., Annual General Meeting, Jul 28, 2022Zhongchao Inc., Annual General Meeting, Jul 28, 2022, at 21:00 China Standard Time. Location: Nanxi Creative Center, Suite 218, 841 Yan’an Middle Road Jing’An District, Shanghai, People’s Republic of China Jing'an China Agenda: To elect each of the five directors named in this notice to shareholders (the “Proxy Statement”) to hold office until the next annual meeting of shareholders and until his/her respective successor is elected and duly qualified; and To approve the appointment of Marcum Bernstein & Pinchuk LLP, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.공시 • May 03Zhongchao Inc. announced delayed 20-F filingOn 05/02/2022, Zhongchao Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.분석 기사 • Apr 14Some Investors May Be Worried About Zhongchao's (NASDAQ:ZCMD) Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 39% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 19x in the Consumer Services industry in the US. Total loss to shareholders of 44% over the past year.분석 기사 • Oct 15Investors Could Be Concerned With Zhongchao's (NASDAQ:ZCMD) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Seeking Alpha • Sep 21Zhongchao Inc.: Ask Why?Zhongchao Inc. is a China-based healthcare information, education, training & services provider. Floated in February 2020, the 3 million share-offering raised circa $12M. Since then, the stock has tanked losing about 60% of its value. The Chinese government’s crackdown on capital raising abroad provides headwinds for China-based equities. Before any investment decision, ask why.공시 • Aug 26Zhongchao Inc.'s Subsidiary Shanghai Zhongxin Medical Technology Co., Ltd Expands Patient Management Business to Ovarian Cancer MarketZhongchao Inc. announced its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin") provides patient follow-up management services for ovarian cancer patients from Zeyoulexiang Patient Assistance Project (the "Project"), helping ovarian cancer patients improve treatment outcomes and eventually increase survival rate. The Project, managed by Bethune Charitable Foundation, provides assistance to female patients in mainland China who meet the standards to take Niraparib, an anti-cancer medication. Through the all-in-one patient management system ("All-in-One System") developed by the Company, patients can record, track and view various indications of their bodies and disease during the medication and receive early warnings of potential disease progression to manage adverse reactions and psychological problems during medication and improve their adherence to treatment and treatment safety. In addition, the digital follow-up function embedded in the All-in-One System allows patient management specialists and physicians to provide one-on-one medication guidance and lifestyle advice for patients to ensure correct drugs usage and response to adverse reactions, improving the treatment experience.Seeking Alpha • Jun 29Zhongchao: Cheap Growth And Value Healthcare Education StockZhongchao is a provider of healthcare education/training/services in China. Lost 56.6% of its value since IPO in March 2020. Price drop mainly caused by struggles to communicate its brand and its value to investors. Operates in a growing and large market. Excellent earnings/revenue valuation and growth rates. The price drop made it cheap too.공시 • May 29Zhongchao Inc. Launches New Line of BusinessZhongchao Inc. announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. Zhongchao has been closely following up on the new study and research of tumor and rare disease both in China and worldwide. Based on the statistics provided by World Health Organization'sInternational Agency for Research on Cancer, there were approximately 19.29 million new cancer cases and 10 million cancer deaths globally in 2020. China had approximately 4.57 million new cancer cases in 2020, accounting for approximately 23.7% of the total cancer cases around the world. China'sNational Health Commission indicated that there are approximately 20 million patients with rare disease in China. Medical treatment markets for both cancer and rare diseases have been expanding along with the increasing number of patients. The Company has realized that, in addition to drug development and more advanced medical treatment options, patients' active engagements in the treatment is also critical to lead to better overall treatment outcomes such as higher chemotherapy completion rate, lower rehospitalization risk and longer survival time. Many multinational pharmaceutical companies have also realized such significance by conducting strategic investments in not only drug developments but also patient management projects. With our MDMOOC online platform which provides information, education, and training services for healthcare professionals and Sunshine Health Forums which provides healthcare knowledge for the public, the Company could provide technical supports for Zhongxin's patient management services to assist patients with tumor or rare disease. Zhongxin plans to build a comprehensive patient management system with integrated data insights into existing clinical workflows.분석 기사 • May 11A Piece Of The Puzzle Missing From Zhongchao Inc.'s (NASDAQ:ZCMD) Share PriceWith a price-to-earnings (or "P/E") ratio of 9.7x Zhongchao Inc. ( NASDAQ:ZCMD ) may be sending very bullish signals at...Reported Earnings • May 03Full year 2020 earnings released: EPS US$0.18 (vs US$0.19 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: US$18.0m (up 21% from FY 2019). Net income: US$4.46m (up 10% from FY 2019). Profit margin: 25% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improved over the past weekAfter last week's 54% share price gain to US$2.66, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 23x in the Consumer Services industry in the US. Total returns to shareholders of 21% over the past year.Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.91, the stock is trading at a trailing P/E ratio of 11.5x, down from the previous P/E ratio of 13.7x. This compares to an average P/E of 25x in the Consumer Services industry in the US. Total return to shareholders over the past year is a loss of 51%.분석 기사 • Feb 23How Much Did Zhongchao's(NASDAQ:ZCMD) Shareholders Earn From Share Price Movements Over The Last Year?While not a mind-blowing move, it is good to see that the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has gained 24% in...Is New 90 Day High Low • Feb 13New 90-day high: US$2.22The company is up 10.0% from its price of US$2.02 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 21% over the same period.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$2.14, the stock is trading at a trailing P/E ratio of 12.9x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 24x in the Consumer Services industry in the US.분석 기사 • Jan 08We're Not So Sure You Should Rely on Zhongchao's (NASDAQ:ZCMD) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...Is New 90 Day High Low • Jan 07New 90-day low: US$1.68The company is down 8.0% from its price of US$1.82 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is down 7.0% over the same period.Valuation Update With 7 Day Price Move • Dec 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.76, the stock is trading at a trailing P/E ratio of 10.6x, down from the previous P/E ratio of 12.7x. This compares to an average P/E of 27x in the Consumer Services industry in the US.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$2.11, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 28x in the Consumer Services industry in the US.Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 18% share price decline to US$1.77, the stock is trading at a trailing P/E ratio of 10.7x, down from the previous P/E ratio of 13x. This compares to an average P/E of 28x in the Consumer Services industry in the US.Valuation Update With 7 Day Price Move • Nov 13Market bids up stock over the past weekAfter last week's 16% share price gain to US$2.15, the stock is trading at a trailing P/E ratio of 13x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 28x in the Consumer Services industry in the US.Is New 90 Day High Low • Oct 03New 90-day low: US$1.70The company is down 21% from its price of US$2.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 12% over the same period.Reported Earnings • Sep 22First half earnings releasedOver the last 12 months the company has reported total profits of US$3.77m, down 10% from the prior year. Total revenue was US$16.4m over the last 12 months, up 12% from the prior year.매출 및 비용 세부 내역Zhongchao가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:ZCMD 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2511-611030 Sep 2512-410030 Jun 2513-28031 Mar 2514-18031 Dec 2416-19030 Sep 2417-49030 Jun 2417-79031 Mar 2418-911031 Dec 2319-1113130 Sep 2318-1013130 Jun 2317-813131 Mar 2316-511031 Dec 2214-39030 Sep 2215-29030 Jun 2215-19031 Mar 221609131 Dec 211609130 Sep 211728130 Jun 211847131 Mar 211847131 Dec 201847130 Sep 201746130 Jun 201646131 Mar 201646131 Dec 191546130 Sep 191545130 Jun 191544131 Mar 191444131 Dec 181334131 Dec 1710241양질의 수익: ZCMD 은(는) 현재 수익성이 없습니다.이익 마진 증가: ZCMD는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ZCMD은 수익성이 없으며 지난 5년 동안 손실이 연평균 42.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ZCMD의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ZCMD은 수익성이 없어 지난 해 수익 성장률을 Consumer Services 업계(10.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ZCMD는 현재 수익성이 없으므로 자본 수익률이 음수(-25.73%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YConsumer-services 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/15 00:05종가2026/05/15 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Zhongchao Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 06Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024)Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024).
Reported Earnings • Oct 05First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024)First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 27Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023)Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 02Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022)Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
Reported Earnings • Dec 27First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 14Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021)Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 06Full year 2025 earnings released: US$1.85 loss per share (vs US$0.99 loss in FY 2024)Full year 2025 results: US$1.85 loss per share (further deteriorated from US$0.99 loss in FY 2024). Revenue: US$11.4m (down 28% from FY 2024). Net loss: US$6.31m (loss widened US$5.67m from FY 2024).
New Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 126% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (126% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).
분석 기사 • Feb 13Zhongchao Inc. (NASDAQ:ZCMD) Looks Inexpensive After Falling 60% But Perhaps Not Attractive EnoughZhongchao Inc. ( NASDAQ:ZCMD ) shareholders that were waiting for something to happen have been dealt a blow with a 60...
New Risk • Feb 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$7.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 52% per year over the past 5 years. Market cap is less than US$10m (US$7.76m market cap). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).
New Risk • Dec 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$18.9m market cap).
분석 기사 • Dec 30Some Zhongchao Inc. (NASDAQ:ZCMD) Shareholders Look For Exit As Shares Take 32% PoundingTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 32% in the last...
Reported Earnings • Oct 05First half 2025 earnings released: US$0.038 loss per share (vs US$0.034 profit in 1H 2024)First half 2025 results: US$0.038 loss per share (down from US$0.034 profit in 1H 2024). Revenue: US$5.60m (down 33% from 1H 2024). Net loss: US$965.3k (down US$1.06m from profit in 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
분석 기사 • Sep 20Zhongchao Inc. (NASDAQ:ZCMD) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedZhongchao Inc. ( NASDAQ:ZCMD ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...
New Risk • Sep 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$24.0m market cap).
분석 기사 • Jun 22What Zhongchao Inc.'s (NASDAQ:ZCMD) 28% Share Price Gain Is Not Telling YouZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...
분석 기사 • Jun 19Here's Why We're Watching Zhongchao's (NASDAQ:ZCMD) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$33.6m market cap).
Reported Earnings • Apr 27Full year 2024 earnings released: US$0.12 loss per share (vs US$4.35 loss in FY 2023)Full year 2024 results: US$0.12 loss per share (improved from US$4.35 loss in FY 2023). Revenue: US$15.9m (down 18% from FY 2023). Net loss: US$643.2k (loss narrowed 94% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
분석 기사 • Feb 28Zhongchao Inc.'s (NASDAQ:ZCMD) Popularity With Investors Is Under Threat From OverpricingIt's not a stretch to say that Zhongchao Inc.'s ( NASDAQ:ZCMD ) price-to-sales (or "P/S") ratio of 1.8x right now seems...
분석 기사 • Nov 15Zhongchao Inc.'s (NASDAQ:ZCMD) 32% Dip In Price Shows Sentiment Is Matching RevenuesZhongchao Inc. ( NASDAQ:ZCMD ) shares have had a horrible month, losing 32% after a relatively good period beforehand...
공시 • Nov 07Zhongchao Inc., Annual General Meeting, Dec 18, 2024Zhongchao Inc., Annual General Meeting, Dec 18, 2024, at 09:00 China Standard Time. Location: nanxi creative center, suite 218, 841 yanan middle road, jingan district, shanghai, China
New Risk • Oct 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 116% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.3m market cap).
공시 • Oct 02Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million.Zhongchao Inc. has filed a Follow-on Equity Offering in the amount of $0.9282 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 3,094,000 Price\Range: $0.3 Discount Per Security: $0 Transaction Features: Registered Direct Offering
분석 기사 • Oct 01Zhongchao Inc. (NASDAQ:ZCMD) Surges 76% Yet Its Low P/S Is No Reason For ExcitementDespite an already strong run, Zhongchao Inc. ( NASDAQ:ZCMD ) shares have been powering on, with a gain of 76% in the...
New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 27% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 68% per year over the past 5 years. Market cap is less than US$10m (US$3.39m market cap).
분석 기사 • Aug 10Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryZhongchao Inc. ( NASDAQ:ZCMD ) shareholders would be excited to see that the share price has had a great month, posting...
Reported Earnings • May 02Full year 2023 earnings released: US$4.35 loss per share (vs US$1.13 loss in FY 2022)Full year 2023 results: US$4.35 loss per share (further deteriorated from US$1.13 loss in FY 2022). Revenue: US$19.4m (up 37% from FY 2022). Net loss: US$11.3m (loss widened 286% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
분석 기사 • Apr 27Zhongchao Inc.'s (NASDAQ:ZCMD) Shares Bounce 32% But Its Business Still Trails The IndustryThose holding Zhongchao Inc. ( NASDAQ:ZCMD ) shares would be relieved that the share price has rebounded 32% in the...
분석 기사 • Mar 07Benign Growth For Zhongchao Inc. (NASDAQ:ZCMD) Underpins Stock's 30% PlummetTo the annoyance of some shareholders, Zhongchao Inc. ( NASDAQ:ZCMD ) shares are down a considerable 30% in the last...
분석 기사 • Dec 28Little Excitement Around Zhongchao Inc.'s (NASDAQ:ZCMD) Revenues As Shares Take 50% PoundingUnfortunately for some shareholders, the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has dived 50% in the last thirty...
Reported Earnings • Dec 27First half 2023 earnings released: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)First half 2023 results: US$0.18 loss per share (down from US$0.004 profit in 1H 2022). Revenue: US$10.4m (up 42% from 1H 2022). Net loss: US$4.72m (down US$4.82m from profit in 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$20.8m market cap).
New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 37% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (4.3% increase in shares outstanding). Market cap is less than US$100m (US$22.4m market cap).
공시 • Sep 26Zhongchao Inc. Introduces Pro-Based Disease Management Model for Lung Cancer PatientsZhongchao Inc. announced the introduction of its Patient-Reported Outcome (PRO)-based symptom management model. This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality. Many lung cancer patients are grappling with a multitude of symptoms throughout their treatment process, including but not limited to fatigue, reduced appetite, nausea, and approximately 34 other symptoms. These symptoms can lead to emotional turmoil towards patients, manifesting as anxiety or depression, severely impacting patients' life quality and their overall recovery process. The PRO-based symptom management method prioritizes genuine feedbacks from patients about their health conditions, which aids in accurately identifying underlying health concerns and enhancing overall well-being. A study published in the "Journal of Clinical Oncology" in 2022 also highlighted that a PRO-driven model integrating proactive Symptom Monitoring, Alerting, and Response System can significantly reduce post-discharge symptoms and complications in lung cancer patients, accelerate their post-operative recovery and receive high satisfaction from patients. Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients. The expert-led seminars could guide patients and offer direct engagement through mobile applications to answer their queries virtually. The seminars ensure patients fully understand their treatment journey and can enhance their adherence to treatment protocols. Zhongchao also provides a suite of resources through mobile applications, including, among the others, educational contents, disease follow-up visits, lifestyle advice, drug aids information and other support services. To facilitate efficient and one-on-one patient communications, Zhongchao has established robust follow-up channels through various platforms such as phones, WeChat, and text messages, staffed by dedicated disease management specialists. Unlike the existing patient management services, which focus primarily on medical aspects such as Duration of Therapy, the newly introduced PRO-based management model shifts the focus towards patients' own experiences and feelings about their health, bringing a fresh perspective into patient care. By actively collecting and analyzing patient feedback on physical symptoms, emotional states, self-perceptions and other PRO data, the Company is able to continually refine its management methods, aiming to enhance the living standards and well-being of lung cancer patients.
Reported Earnings • May 14Full year 2022 earnings released: US$0.11 loss per share (vs US$0.01 profit in FY 2021)Full year 2022 results: US$0.11 loss per share (down from US$0.01 profit in FY 2021). Revenue: US$14.2m (down 13% from FY 2021). Net loss: US$2.94m (down US$3.18m from profit in FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
공시 • Feb 09Zhongchao Inc. Announces the Application of ChatGPT to Elevate Patient Management Service Capabilities and ExperienceZhongchao Inc. announced the application of ChatGPT (Chat Generative Pre-trained Transformer) for content creation and patient interactions to enhance the capabilities in delivering quality experience of patient management services. ChatGPT is a language model developed by OpenAI that learns and produces conversational content through natural language processing powered by artificial intelligence technology to interact with users in chat and continuously learn to improve the user experience. The Sunshine Health Forums and Zhongxin, both operated by the PRC operating entities that Zhongchao consolidates the financial statements with through certain contractual agreements, provide medical knowledge education and treatment process management services with patients through a comprehensive array of resources, including media matrix, anti-cancer encyclopedia, online consultation, and medication management. These platforms offer patients with instant answers and clarifications for complex and professional issues and questions encountered during self-diagnosis, diagnostic and treatment process, serving as a valuable reference for patients' consultation, treatment, and health maintenance. Given the wide variety of human diseases and the huge amount of medical information, patient management requires efficient production of massive medical content and prompt patient interactions. In a further effort to enhance patient experience, Zhongchao will apply ChatGPT on the existing platforms of Wechat Public Account and Mini-Program on WeChat to improve the efficiency of producing graphics, videos, and other contents, promptly respond and interact with patients, and manage patient emotions and experiences. Zhongchao places a strong emphasis on delivering a superior patient experience. In addition, patients will be alerted that contents provided by ChatGPT will be solely for reference and convenience to users and shall not be relied on for diagnostic or treatment purposes. To address patients' demand for personalized services, the Company may plan to harness ChatGPT's power of advanced thinking and computing capabilities to develop customized disease management models and intelligent tools that cater to the specific needs and conditions of each patient, ensuring patients receiving individualized and tailored services regardless of their varying disease types, stages, health conditions, and mental states.
Reported Earnings • Dec 18First half 2022 earnings released: EPS: US$0.004 (vs US$0.04 in 1H 2021)First half 2022 results: EPS: US$0.004 (down from US$0.04 in 1H 2021). Revenue: US$7.30m (down 15% from 1H 2021). Net income: US$93.5k (down 91% from 1H 2021). Profit margin: 1.3% (down from 12% in 1H 2021). The decrease in margin was driven by lower revenue.
공시 • Dec 06Zhongchao Inc. Establishes SID Liver Cancer Comprehensive-Disciplinary Physician Education PlatformZhongchao Inc. announced that after three years of preparation, the Company's MDMOOC platform has established a "Surgical-Interventional-Drug" ("SID") platform for liver cancer comprehensive-disciplinary physician education ("SID Platform"), providing physicians with knowledge and techniques in comprehensive-disciplinary comprehensive management of patients with liver cancer. The SID Platform created by Zhongchao targets physicians from different levels and covers comprehensive disciplines of liver cancer treatment: hepatobiliary surgery, interventional and medical oncology. Led by the Key Opinion Leaders ("KOL") of liver cancer disciplines, the SID Platform designs and provides clinical diagnosis and treatment education courses in liver cancer and provides a technical platform for clinicians to share experiences and discuss clinical challenges. As of now, the courses on the SID Platform were taken approximately 290,000 times by liver cancer physicians. Zhongchao believes that its SID Platform provides a platform for liver cancer physicians, especially for junior and intermediate physicians to present themselves, learn knowledge and techniques, and communicate with peers, which promotes new liver cancer treatment concepts such as conversion therapy, comprehensive patient management and standardized interventional treatments. Zhongchao expects its SID Platform to serve as a new model of promotion and education platform, contribute to the lifelong learning and professional development of liver cancer physicians, and eventually benefit liver cancer patients.
Board Change • Dec 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Kevin Dean Vassily was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Sep 02Zhongchao Inc. Announces Its New Strategy Extension Focusing on the Oncology and Other Major Disease ManagementZhongchao Inc. announced its newly added business section of oncology and other major disease management which is a part of its development strategy to extend its business model from "Medical-Pharmaceutical" to "Medical-Pharmaceutical-Patient." Utilizing its accumulated experiences in medical education and innovation, and extensive resources with medical professionals and pharmaceuticals, Zhongchao is well positioned to become a platform that provides patients with major disease management services. The Company has implemented several strategic initiatives to transform to the new "Medical-Pharmaceutical-Patient" model. In 2021, Zhongchao launched patient management business focusing on the professional field of tumor and rare disease through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin"), which was the important first step of the transform. The strategy to extend business model was driven by the increased demands of "patient-oriented" healthcare in China. Management have been closely observing and monitoring such service model that is to provide medical services and disease management tailored to individual patient and allow patient to actively initiate and participate in health management and disease treatment since its appearance in 2021. It is worth to mention that the Company's self-developed patient management system successfully improved Duration of Therapy ("DOT") by 40.4% for liver cancer patients, contributing to the maximum efficiency of drugs, successful treatment and longer patient survival terms, as compared to patients without using the management system, based on the data collected by the Company during a period from November 2017 to September 2021. As a result, the Company plans to continue the development of patient management services through Zhongxin. As of now, Zhongxin provides comprehensive disease education and management services for tumor patients receiving treatment. Through services such as drug aids, disease follow-up visits, medication management, and cancer education promotion, Zhongxin helps tumor patients reduce the economic burden of treatment and promote the completion the treatment process, resulting in the best treatment effect and improvement the quality of life for the patients. As of now, more than hundreds of thousand oncology Patients have used either the application developed by Zhongxin or WeChat network service platform to connect patients with Zhongxin's hotline center and service commissioner system and received disease management support.
공시 • Jun 15Zhongchao Inc., Annual General Meeting, Jul 28, 2022Zhongchao Inc., Annual General Meeting, Jul 28, 2022, at 21:00 China Standard Time. Location: Nanxi Creative Center, Suite 218, 841 Yan’an Middle Road Jing’An District, Shanghai, People’s Republic of China Jing'an China Agenda: To elect each of the five directors named in this notice to shareholders (the “Proxy Statement”) to hold office until the next annual meeting of shareholders and until his/her respective successor is elected and duly qualified; and To approve the appointment of Marcum Bernstein & Pinchuk LLP, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022.
공시 • May 03Zhongchao Inc. announced delayed 20-F filingOn 05/02/2022, Zhongchao Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
분석 기사 • Apr 14Some Investors May Be Worried About Zhongchao's (NASDAQ:ZCMD) Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment deteriorated over the past weekAfter last week's 39% share price decline to US$1.05, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 19x in the Consumer Services industry in the US. Total loss to shareholders of 44% over the past year.
분석 기사 • Oct 15Investors Could Be Concerned With Zhongchao's (NASDAQ:ZCMD) Returns On CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Seeking Alpha • Sep 21Zhongchao Inc.: Ask Why?Zhongchao Inc. is a China-based healthcare information, education, training & services provider. Floated in February 2020, the 3 million share-offering raised circa $12M. Since then, the stock has tanked losing about 60% of its value. The Chinese government’s crackdown on capital raising abroad provides headwinds for China-based equities. Before any investment decision, ask why.
공시 • Aug 26Zhongchao Inc.'s Subsidiary Shanghai Zhongxin Medical Technology Co., Ltd Expands Patient Management Business to Ovarian Cancer MarketZhongchao Inc. announced its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. ("Zhongxin") provides patient follow-up management services for ovarian cancer patients from Zeyoulexiang Patient Assistance Project (the "Project"), helping ovarian cancer patients improve treatment outcomes and eventually increase survival rate. The Project, managed by Bethune Charitable Foundation, provides assistance to female patients in mainland China who meet the standards to take Niraparib, an anti-cancer medication. Through the all-in-one patient management system ("All-in-One System") developed by the Company, patients can record, track and view various indications of their bodies and disease during the medication and receive early warnings of potential disease progression to manage adverse reactions and psychological problems during medication and improve their adherence to treatment and treatment safety. In addition, the digital follow-up function embedded in the All-in-One System allows patient management specialists and physicians to provide one-on-one medication guidance and lifestyle advice for patients to ensure correct drugs usage and response to adverse reactions, improving the treatment experience.
Seeking Alpha • Jun 29Zhongchao: Cheap Growth And Value Healthcare Education StockZhongchao is a provider of healthcare education/training/services in China. Lost 56.6% of its value since IPO in March 2020. Price drop mainly caused by struggles to communicate its brand and its value to investors. Operates in a growing and large market. Excellent earnings/revenue valuation and growth rates. The price drop made it cheap too.
공시 • May 29Zhongchao Inc. Launches New Line of BusinessZhongchao Inc. announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co. Ltd. Zhongchao has been closely following up on the new study and research of tumor and rare disease both in China and worldwide. Based on the statistics provided by World Health Organization'sInternational Agency for Research on Cancer, there were approximately 19.29 million new cancer cases and 10 million cancer deaths globally in 2020. China had approximately 4.57 million new cancer cases in 2020, accounting for approximately 23.7% of the total cancer cases around the world. China'sNational Health Commission indicated that there are approximately 20 million patients with rare disease in China. Medical treatment markets for both cancer and rare diseases have been expanding along with the increasing number of patients. The Company has realized that, in addition to drug development and more advanced medical treatment options, patients' active engagements in the treatment is also critical to lead to better overall treatment outcomes such as higher chemotherapy completion rate, lower rehospitalization risk and longer survival time. Many multinational pharmaceutical companies have also realized such significance by conducting strategic investments in not only drug developments but also patient management projects. With our MDMOOC online platform which provides information, education, and training services for healthcare professionals and Sunshine Health Forums which provides healthcare knowledge for the public, the Company could provide technical supports for Zhongxin's patient management services to assist patients with tumor or rare disease. Zhongxin plans to build a comprehensive patient management system with integrated data insights into existing clinical workflows.
분석 기사 • May 11A Piece Of The Puzzle Missing From Zhongchao Inc.'s (NASDAQ:ZCMD) Share PriceWith a price-to-earnings (or "P/E") ratio of 9.7x Zhongchao Inc. ( NASDAQ:ZCMD ) may be sending very bullish signals at...
Reported Earnings • May 03Full year 2020 earnings released: EPS US$0.18 (vs US$0.19 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: US$18.0m (up 21% from FY 2019). Net income: US$4.46m (up 10% from FY 2019). Profit margin: 25% (down from 27% in FY 2019). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improved over the past weekAfter last week's 54% share price gain to US$2.66, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 23x in the Consumer Services industry in the US. Total returns to shareholders of 21% over the past year.
Valuation Update With 7 Day Price Move • Feb 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.91, the stock is trading at a trailing P/E ratio of 11.5x, down from the previous P/E ratio of 13.7x. This compares to an average P/E of 25x in the Consumer Services industry in the US. Total return to shareholders over the past year is a loss of 51%.
분석 기사 • Feb 23How Much Did Zhongchao's(NASDAQ:ZCMD) Shareholders Earn From Share Price Movements Over The Last Year?While not a mind-blowing move, it is good to see that the Zhongchao Inc. ( NASDAQ:ZCMD ) share price has gained 24% in...
Is New 90 Day High Low • Feb 13New 90-day high: US$2.22The company is up 10.0% from its price of US$2.02 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 21% over the same period.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$2.14, the stock is trading at a trailing P/E ratio of 12.9x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 24x in the Consumer Services industry in the US.
분석 기사 • Jan 08We're Not So Sure You Should Rely on Zhongchao's (NASDAQ:ZCMD) Statutory EarningsStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
Is New 90 Day High Low • Jan 07New 90-day low: US$1.68The company is down 8.0% from its price of US$1.82 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is down 7.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$1.76, the stock is trading at a trailing P/E ratio of 10.6x, down from the previous P/E ratio of 12.7x. This compares to an average P/E of 27x in the Consumer Services industry in the US.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 20% share price gain to US$2.11, the stock is trading at a trailing P/E ratio of 12.7x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 28x in the Consumer Services industry in the US.
Valuation Update With 7 Day Price Move • Nov 19Market pulls back on stock over the past weekAfter last week's 18% share price decline to US$1.77, the stock is trading at a trailing P/E ratio of 10.7x, down from the previous P/E ratio of 13x. This compares to an average P/E of 28x in the Consumer Services industry in the US.
Valuation Update With 7 Day Price Move • Nov 13Market bids up stock over the past weekAfter last week's 16% share price gain to US$2.15, the stock is trading at a trailing P/E ratio of 13x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 28x in the Consumer Services industry in the US.
Is New 90 Day High Low • Oct 03New 90-day low: US$1.70The company is down 21% from its price of US$2.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Services industry, which is up 12% over the same period.
Reported Earnings • Sep 22First half earnings releasedOver the last 12 months the company has reported total profits of US$3.77m, down 10% from the prior year. Total revenue was US$16.4m over the last 12 months, up 12% from the prior year.